Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension

Figures & data

Table I. Demographics of the study patient cohort.

	Zofenopril	Atenolol	p‐value
n	153	151
Gender (male/female)	68/85	78/73	0.208
Age (years)	55.0±9.8	53.2±11.9	0.153
Body mass index	26.2±2.1	26.5±2.3	0.242
Previously treated/untreated	143/10	136/15	0.281
Sitting SBP/DBP (mmHg)	156.1±10.4/100.4±3.5	154.3±11.1/100.4±3.5	0.144/0.904
Sitting HR (beats/min)	75.0±8.1	75.0±8.3	0.905

Shown are actual numbers or means±SD. Statistical comparison by Student t‐test or Fisher's exact probability test. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.

Table II. Sitting systolic (SBP) and diastolic blood pressures (DBP) in zofenopril and atenolol treated patients during 12 weeks of follow‐up.

	Zofenopril (SBP/DBP)	Atenolol (SBP/DBP)	p‐value
Baseline	156.0±10.4/100.5±3.5	154.6±11.1/100.5±3.8
Week 2	142.1±12.7/89.2±6.7	143.0±12.5/90.7±5.9	0.046/0.033
Week 4	140.4±11.7/87.0±6.6	141.5±12.2/88.7±6.3	0.035/0.024
Week 8	139.0±10.1/87.1±6.2	140.0±11.3/88.7±6.3	0.042/0.303
Week 12	140.1±11.9/86.5±4.8	139.9±11.9/88.8±5.7	0.329/0.689

Shown are means±SD of blood pressure values in mmHg from the 12 weeks intention‐to‐treat population (zofenopril 30–60 mg od = 127; atenolol 50–100 mg od = 127). Dose up‐titration was optional in non‐responders at week 4. Statistical comparison between treatments denotes baseline corrected differences between treatments by ANOVA. SBP and DBP reductions at weeks 2, 4, 8, 6 or 12 vs baseline value all p<0.001.

Table III. Response rates (sitting diastolic blood pressure <90 mmHg, and/or decrease in sitting diastolic blood pressure by at least 10 mmHg from baseline) and control rates (sitting diastolic blood pressure <90 mmHg) after 12 weeks of treatment by zofenopril or atenolol.

	Zofenopril, n (%)	Atenolol, n (%)	p‐value
Responder	130 (90.9)	123 (85.4)	0.150
Non‐responder	13 (9.1)	21 (14.8)
Controlled	115 (80.4)	97 (67.4)	0.012
Non‐controlled	28 (19.6)	47 (32.6)

Table IV. Adverse events (AEs) during exposure to the study medications.

	Zofenopril	Atenolol	p‐value
n	153	151
Subjects with AEs	31	40	0.199
Subjects with AEs possibly, probably or definitely drug related	14	30	0.008
Severity of AEs (all events)			0.039
Mild	51	71
Moderate	5	23
Severe	2	7
Severity of AEs possibly, probably or definitely drug related			0.069
Mild	17	34
Moderate	1	17
Severe	2	6

Shown are actual numbers of subjects with events as well as number of events in zofenopril and atenolol treated patients over the course of the trial. Statistical comparison by chi‐squared test.